13 results about "Clinical reaction" patented technology

The discovery and application of immune checkpoint inhibitors (ICI) have significantly promoted cancer treatment. However, the response rate is still low in gastrointestinal (GI) cancers. To explore novel adjuvant treatment options, we performed fecal microbiota transplantation (FMT) of healthy donors on 10 GI cancer patients with resistance to anti-PD-(L) 1 treatment. The combination of FMT and anti-PD1 treatment was well tolerated and no serious adverse reaction was observed. Two out of 10 patients restored clinical responsiveness to anti-PD1 after FMT. Clinical benefits were shown to be associated with better colonization of co-occurred immunogenic microbes from donors, alongside activated immune status reflected by the peripheral immune cell population. Moreover, we identified microbial signatures of ICI responsiveness and validated in an independent cohort. Our study demonstrates the feasibility of FMT as a potential adjuvant therapy for ICI irresponsive GI cancer patients and laid a foundation for LBP / consortia development to enhance ICI efficacy.

The utility model discloses a clinical response recording device which comprises an image recording assembly, the image recording assembly comprises a workbench, an electric lifting rod is arranged on the outer wall of the top of the workbench, a rotating motor is arranged on the top of the electric lifting rod, a rotating shaft is connected to the top of the rotating motor, and a mounting base is arranged on the outer wall of the top of the rotating shaft. A driving motor is arranged on the outer wall of one side of the mounting base, one side of the driving motor is connected with a transmission shaft, one end of the transmission shaft rotatably penetrates through the mounting base, an adjusting frame is mounted at one end of the transmission shaft, a camera is mounted at the top of the adjusting frame, and a fixing frame is mounted at one end of the electric lifting rod; a storage assembly used for storing articles is arranged on one side of the workbench and comprises a storage cabinet, the storage cabinet is fixed to the outer wall of the bottom of the workbench, multiple sets of mounting grooves are formed in the inner walls of the two sides of the storage cabinet, a drawing frame is slidably mounted through the mounting grooves, and a storage box is arranged on one side of the drawing frame.

The present invention relates to the technical field of diagnostic markers, and in particular to a marker for evaluating the efficacy of PD-1 in treating melanoma and its application. Research conducted in the present invention has shown that extracellular vesicle PD-L2 is associated with the clinical response to anti-PD-1 therapy, and its changes are a more reliable biomarker for predicting the prognosis of melanoma patients receiving anti-PD-1 therapy. The baseline level of PD-L2 on the EV membrane and the dynamic changes of PD-L2 on the EV membrane can serve as predictors of the outcome of melanoma immunotherapy and play an important role in evaluating the prognostic effect.

Provided herein are methods for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered an organic anion transporter-1 (OAT1) substrate to treat an associated disease or disorder. The method comprises administering to the subject a therapeutically effective amount of dichlorphenamide, or a pharmaceutically acceptable salt thereof, and monitoring the subject for signs and symptoms of toxicity and clinical response associated with the OAT1 substrate.

To provide a combination with previously-proven cancer therapies such as anti-angiogenic agents in order to improve clinical response rates to anti-PD1 antibodies.SOLUTION: An antibody or an antigen-binding fragment thereof that binds specifically to both PD1 and VEGFR2, and a pharmaceutical composition comprising the same, are provided.SELECTED DRAWING: None

A clinical decision support system and method for predicting a clinical response of a target tumor to an immune checkpoint blocking therapy (ICB) by: obtaining a training dataset, the training dataset comprising training transcriptome records of tumor tissue samples of a plurality of known responders and a plurality of known non-responders to the ICB; deconvolution is carried out on the training data set to identify differential expression genes DEG in the training data set, the DEG is regarded as features of the training data set, and related responder and non-responder states are regarded as labels recorded in the training data set; performing regression analysis on the features to select a feature subset which can predict the responder tag or the non-responder tag and related feature weights; incorporating the feature subset and the associated feature weight into a reaction estimation model; receiving transcriptome data of the target tumor tissue sample; the transcriptome data is processed using the generated response estimation model to generate an estimated response indicator indicative of a possible response of the target tumor to the ICB.

This disclosure provides a diagnostic method, which can be used in combination with medical intervention, that uses one or more plasma biomarkers useful for identifying subjects with hidradenitis suppurativa (HS), measures the disease severity of HS, and measures the clinical response in subjects with HS. This disclosure relates to a method for testing for hidradenitis suppurativa (HS) in a subject, comprising measuring one or more plasma biomarkers in a sample taken from the subject, wherein one or more plasma biomarkers are selected from the group consisting of IL8, IL36β, MDC, and TNFα.

Provided herein are methods in which a patient is administered benglustat in combination with an inhibitor of cytochrome CYP3A4, which may involve making specific adjustments to the benglustat dosage to optimize the patient's clinical response.

The present disclosure relates to methods for using various markers to predict manufacturing outcomes or clinical responses of subjects, e.g., patients, to administration of a T cell therapy. In some aspects, the T cells of the T cell therapy express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs), or other transgenic receptors, such as T cell receptors (TCRs). Also provided herein are methods for treating subjects, for instance those predicted to exhibit a clinical response.

Provided herein are methods of administering to a patient a combination of venlustat and an inhibitor of cytochrome CYP3A4. These methods can involve specific adjustments to the dosage of venlustat in order to optimize the clinical response of a patient.

The present invention relates to food allergen compositions. In particular, the present invention relates to novel compositions and methods for the diagnosis or treatment of food allergies. Specifically, the present invention discloses a novel method of delivering food allergens to an allergic patient by oral administration of a formulation that dissolves and releases the proteins in the stomach. The present invention allows for the treatment of food allergies by delivering food allergens to the intestinal immune system and controlled exposure to the esophagus or oral cavity. The present invention also allows for the assessment of the threshold of clinical reactivity by food provocation without exposure to the esophagus and oral cavity. The present invention can be used in any subject, particularly a human subject, and is applicable to any food allergen.

Methods for predicting whether a subject with asthma will respond to asthma therapy and / or will achieve asthma remission using biomarkers are provided. Methods of treating asthma in a subject with an increased expression level of at least one biomarker or a biomarker set are provided. Methods for predicting whether a subject with asthma will respond to asthma therapy and / or will achieve asthma by measuring ciliated cell levels, e.g., epithelial ciliated cell levels and / or epithelial proximal ciliated cell levels, are provided.

Methods for predicting whether a subject with asthma will respond to asthma therapy and / or will achieve asthma remission using biomarkers are provided. Methods of treating asthma in a subject with an increased expression level of at least one biomarker or a biomarker set are provided. Methods for predicting whether a subject with asthma will respond to asthma therapy and / or will achieve asthma by measuring ciliated cell levels, e.g., epithelial ciliated cell levels and / or epithelial proximal ciliated cell levels, are provided.